VPS35 Protein Acts as Cellular ROS Sensor to Control Mitochondrial Function
New research reveals how cells sense dangerous oxygen levels and protect themselves by shutting down energy production in mitochondria.
Summary
Scientists discovered that VPS35, a protein involved in cellular trafficking, acts as a sensor for reactive oxygen species (ROS). When ROS levels rise, specific amino acids in VPS35 become oxidized, causing the protein to change shape and trigger a protective response. This leads to reduced mitochondrial protein production, which lowers dangerous ROS levels. The finding explains how cells maintain the delicate balance between beneficial and harmful oxygen species, and reveals why some cancer treatments become less effective when this pathway is disrupted.
Detailed Summary
Reactive oxygen species (ROS) are essential for normal cell function but become toxic at high levels, contributing to cancer and neurodegeneration. While mitochondria are known as major ROS producers, the mechanisms cells use to sense and control ROS levels have remained poorly understood. Researchers at Massachusetts General Hospital used advanced CRISPR screening techniques to identify which of 25,000+ cellular proteins containing cysteine amino acids might serve as ROS sensors.
The team discovered that VPS35, a core component of the Retromer protein trafficking complex, contains two critical cysteine residues (Cys653 and Cys673) that become oxidized when cellular hydrogen peroxide levels rise. This oxidation causes VPS35 to detach from cellular membranes, disrupting the normal trafficking of proteins to the cell surface. Most importantly, this leads to mislocalization of SLC7A1, an amino acid transporter essential for mitochondrial protein synthesis.
When VPS35 is oxidized, mitochondrial translation decreases significantly while cytosolic protein production remains unchanged. This selective reduction in mitochondrial protein synthesis effectively lowers ROS production, creating a protective feedback loop. The researchers tested this mechanism across 40+ cancer cell lines representing 18 different tissue types, finding consistent effects when mitochondrial translation was inhibited.
The clinical implications are significant for cancer treatment. The study found that ovarian cancer patients with lower VPS35 levels developed platinum-based chemotherapy resistance more quickly. In laboratory models, reducing VPS35 levels or expressing oxidation-mimicking mutants conferred resistance to cisplatin and other ROS-generating cancer drugs. This suggests that tumors may exploit this natural protective mechanism to survive chemotherapy.
While this research provides crucial insights into cellular ROS regulation, the findings come primarily from cell culture studies and require validation in human clinical trials. The work opens new avenues for understanding how cells balance beneficial versus harmful oxidative stress and may lead to strategies for overcoming chemotherapy resistance.
Key Findings
- VPS35 contains two ROS-sensing cysteines (Cys653/Cys673) that become oxidized by hydrogen peroxide
- Oxidation of VPS35 causes Retromer complex dissociation from endosomal membranes
- VPS35 oxidation leads to mislocalization of amino acid transporter SLC7A1 from plasma membrane
- Mitochondrial translation decreases while cytosolic translation remains unchanged when VPS35 is oxidized
- Lower VPS35 levels correlate with faster platinum resistance development in ovarian cancer patients
- VPS35 depletion or oxidation-mimicking mutations confer cisplatin resistance in cancer models
- Screening of 25,000+ cysteines identified 583 resistance-mediating and 1,801 sensitivity-mediating residues
Methodology
Researchers used CRISPR cytosine base editing to systematically mutate 25,000+ cysteine residues across the proteome in K562 and HEK-293T cell lines. Cells were treated with four ROS-generating anti-cancer drugs (auranofin, arsenic trioxide, β-lapachone, cisplatin) or nuclear hydrogen peroxide via D-amino acid oxidase. Functional effects were measured through cell surface proteomics, mitochondrial translation assays, and drug sensitivity testing across 40+ cancer cell lines representing 18 tissue types.
Study Limitations
The study was conducted primarily in cell culture models, with limited validation in human tissue samples from ovarian cancer patients. The researchers acknowledge that translation to clinical applications requires additional human studies. The work focused on cancer cell lines, so applicability to normal aging processes and other diseases needs further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.